EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma with Tumor Spread Through Air Spaces: A Multi-Center Real-World Study

Hanbo Pan, Weiyang Huang, Wanlin Yang, Ling Li, Zhen Ge, Weicheng Kong, Hang Chen, Yu Tian, Wanyu Li, Junwei Ning, Liang Fang, Zhongjie Chen und 11 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.09.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Hanbo Pan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, National Health Commission of the People's Republic of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of adjuvant chemotherapy (ACT) for stage IA lung adenocarcinoma (LUAD) with tumor spread through air spaces (STAS) remains inconclusive. This study aimed to evaluate the efficacy of ACT in stage IA STAS+ LUAD patients and to identify subpopulations that might derive clinically significant benefits from ACT. METHODS: Consecutive pathological stage IA (T1a-cN0M0) STAS+ LUAD patients who underwent surgery, with or without ACT, between 2012 and 2020 across 6 high-volume centers were retrospectively reviewed. Propensity-score matching (PSM) was performed to minimize selection bias. The primary endpoint was overall survival. Clinically significant survival benefits were predefined as a hazard ratio (HR) 5%. RESULTS: Among 3026 eligible cases, 2619 patients (873 ACT and 1746 no ACT) were matched by PSM, achieving well-balanced clinicopathological characteristics. Over a median follow-up of 6.88 years, ACT did not confer clinically significant improvements in overall survival (hazard ratio = 0.795, P = .010) in the overall cohort. Cox regression analyses identified age, histology subtype, lymphovascular invasion (LVI), resection extent, and pathological stage as independent prognostic factors. Interaction analyses further revealed that histology subtype, LVI, and resection extent, but not age or pathological stage, modified ACT's effect on survival. Exploratory stratified analyses demonstrated that ACT may be associated with clinically significant survival benefits among patients undergoing sub-lobectomy, those with LVI+ tumors, and those with solid/micropapillary-predominant histology. CONCLUSIONS: Although ACT demonstrated limited clinical survival benefit for the overall stage IA STAS+ LUAD population, it may be necessary for selected high-risk subgroups, specifically those undergoing sub-lobectomy, with LVI+ tumors, or with solid/micropapillary-predominant histology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungHumansMaleFemaleChemotherapy, AdjuvantRetrospective StudiesMiddle AgedAgedNeoplasm StagingSurvival RateFollow-Up StudiesPrognosisPneumonectomy

Stichwörter der Autor:innen

Propensity-score matchingSurvival outcomes

Autor:innen und Institutionen

  • Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic Surgery, Xiangshan First People's Hospital, Ningbo, China.
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Cardiothoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of Thoracic Surgery, Putuo District People's Hospital, Zhoushan, China.
  • Department of Cardiothoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.

Förderung

  • Medical Science and Technology Project of Zhejiang Province
  • National Health Commission of the People's Republic of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Pan, H., Huang, W., Yang, W., Li, L., Ge, Z., Kong, W., Chen, H., Tian, Y., Li, W., Ning, J., Fang, L., Chen, Z., Ruan, G., Dai, Z., Zheng, M., Zhang, M., Wang, H., Niu, X., Huang, J., …, & Luo, Q. (2025). Efficacy of Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma with Tumor Spread Through Air Spaces: A Multi-Center Real-World Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.09.004

Vancouver

Pan H, Huang W, Yang W, Li L, Ge Z, Kong W, et al. Efficacy of Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma with Tumor Spread Through Air Spaces: A Multi-Center Real-World Study. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.09.004

BibTeX
@article{Pan2025,
  author = {Pan, Hanbo and Huang, Weiyang and Yang, Wanlin and Li, Ling and Ge, Zhen and Kong, Weicheng and Chen, Hang and Tian, Yu and Li, Wanyu and Ning, Junwei and Fang, Liang and Chen, Zhongjie and Ruan, Guomo and Dai, Zhizhuo and Zheng, Min and Zhang, Ming and Wang, Hui and Niu, Xiaomin and Huang, Jia and Yin, Hui and Zhou, Chengwei and Xu, Guodong and Luo, Qingquan},
  title = {Efficacy of Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma with Tumor Spread Through Air Spaces: A Multi-Center Real-World Study},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.09.004}
}
Kostenlos starten →